MX362512B - Composiciones purificadas de celulas madre mesenquimales y metodos para purificar composiciones de celulas madre mesenquimales. - Google Patents

Composiciones purificadas de celulas madre mesenquimales y metodos para purificar composiciones de celulas madre mesenquimales.

Info

Publication number
MX362512B
MX362512B MX2014008542A MX2014008542A MX362512B MX 362512 B MX362512 B MX 362512B MX 2014008542 A MX2014008542 A MX 2014008542A MX 2014008542 A MX2014008542 A MX 2014008542A MX 362512 B MX362512 B MX 362512B
Authority
MX
Mexico
Prior art keywords
mesenquimal
compositions
mother
purify
methods
Prior art date
Application number
MX2014008542A
Other languages
English (en)
Spanish (es)
Inventor
Danilkovich Alla
e newman Robert
Tom Samson
Ton Christopher
Wang Zhanling
Young Randal
Original Assignee
Mesoblast Int Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41669330&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX362512(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mesoblast Int Sarl filed Critical Mesoblast Int Sarl
Publication of MX362512B publication Critical patent/MX362512B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
MX2014008542A 2008-08-14 2009-08-14 Composiciones purificadas de celulas madre mesenquimales y metodos para purificar composiciones de celulas madre mesenquimales. MX362512B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8889808P 2008-08-14 2008-08-14
PCT/US2009/053891 WO2010019886A1 (en) 2008-08-14 2009-08-14 Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions

Publications (1)

Publication Number Publication Date
MX362512B true MX362512B (es) 2019-01-22

Family

ID=41669330

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014008542A MX362512B (es) 2008-08-14 2009-08-14 Composiciones purificadas de celulas madre mesenquimales y metodos para purificar composiciones de celulas madre mesenquimales.
MX2011001730A MX2011001730A (es) 2008-08-14 2009-08-14 Composiciones purificadas de celulas madre mesenquimales y metodos para purificar composiciones de celulas madre mesenquimales.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2011001730A MX2011001730A (es) 2008-08-14 2009-08-14 Composiciones purificadas de celulas madre mesenquimales y metodos para purificar composiciones de celulas madre mesenquimales.

Country Status (14)

Country Link
US (6) US8637004B2 (https=)
EP (3) EP3124601A1 (https=)
JP (7) JP6025329B2 (https=)
AR (2) AR073069A1 (https=)
AU (1) AU2009281809B2 (https=)
BR (1) BRPI0917993B8 (https=)
CA (1) CA2733985C (https=)
DK (1) DK2318519T3 (https=)
ES (1) ES2608974T3 (https=)
IL (1) IL211214A0 (https=)
MX (2) MX362512B (https=)
NZ (2) NZ602248A (https=)
WO (1) WO2010019886A1 (https=)
ZA (1) ZA201101858B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298864B1 (en) 2004-03-22 2017-10-11 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US20070258963A1 (en) 2006-01-13 2007-11-08 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptors
WO2010019886A1 (en) 2008-08-14 2010-02-18 Osiris Therapeutics, Inc. Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions
KR20200011604A (ko) 2008-08-20 2020-02-03 안트로제네시스 코포레이션 개선된 세포 조성물 및 그의 제조 방법
US9192695B2 (en) 2008-11-20 2015-11-24 Allosource Allografts combined with tissue derived stem cells for bone healing
US20140286911A1 (en) 2013-03-15 2014-09-25 Allosource Cell repopulated collagen matrix for soft tissue repair and regeneration
EP2625264B1 (en) 2010-10-08 2022-12-07 Terumo BCT, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
US20120087933A1 (en) * 2010-10-08 2012-04-12 Samson Tom Enhanced msc preparations
ITGE20120034A1 (it) * 2012-03-28 2013-09-29 Carlo Tremolada Preparato e metodo per la produzione di un preparato comprendente cellule staminali mesenchimali
JP2013252126A (ja) * 2012-05-08 2013-12-19 Otsuka Pharmaceut Factory Inc デキストラン含有肺塞栓形成予防用哺乳動物細胞懸濁液
JP6633522B2 (ja) 2013-11-16 2020-01-22 テルモ ビーシーティー、インコーポレーテッド バイオリアクターにおける細胞増殖
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US10251990B2 (en) 2016-04-29 2019-04-09 Fenwal, Inc. System and method for processing, incubating, and/or selecting biological cells
US10449283B2 (en) * 2016-04-29 2019-10-22 Fenwal, Inc. System and method for selecting and culturing cells
JP7034949B2 (ja) 2016-05-25 2022-03-14 テルモ ビーシーティー、インコーポレーテッド 細胞の増殖
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
EP3338823B1 (en) 2016-12-21 2021-06-16 Fenwal, Inc. System and method for separating cells incorporating magnetic separation
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
CN119033819A (zh) 2017-11-22 2024-11-29 迈索布拉斯特国际有限公司 细胞组合物及治疗方法
KR20210003813A (ko) 2018-04-18 2021-01-12 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 LAG-3 항원 결합 도메인을 함유하는 LAG-3 표적화 이종이량체 융합 단백질
EP3847241A1 (en) * 2018-10-26 2021-07-14 Stemselect Method and apparatus for mesenchymal stem cells isolation and purification
CN113438961A (zh) 2018-12-20 2021-09-24 Xencor股份有限公司 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
TW202110463A (zh) * 2019-05-15 2021-03-16 美商永生生技股份有限公司 高濃度細胞包裝和運送
WO2021144995A1 (ja) * 2020-01-16 2021-07-22 ＰｕＲＥＣ株式会社 高純度間葉系幹細胞
EP4146787A4 (en) 2020-05-08 2024-06-26 Gallant Pet, Inc. Uterine-derived regenerative cell compositions and uses thereof
GB2619893A (en) 2021-03-23 2023-12-20 Terumo Bct Inc Cell capture and expansion
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
CN115478046A (zh) * 2022-09-30 2022-12-16 浙江泉生生物科技有限公司 一种降低血清培养体系中细胞制剂bsa残留量的方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034135A (en) 1982-12-13 1991-07-23 William F. McLaughlin Blood fractionation system and method
US4803075A (en) * 1986-06-25 1989-02-07 Collagen Corporation Injectable implant composition having improved intrudability
EP0277994B1 (en) 1986-08-11 1991-09-04 BAXTER INTERNATIONAL INC. (a Delaware corporation) Blood cell washing systems and methods
US5536475A (en) 1988-10-11 1996-07-16 Baxter International Inc. Apparatus for magnetic cell separation
US5197985A (en) 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5226914A (en) 1990-11-16 1993-07-13 Caplan Arnold I Method for treating connective tissue disorders
US5837539A (en) 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US5234608A (en) 1990-12-11 1993-08-10 Baxter International Inc. Systems and methods for processing cellular rich suspensions
CA2192103C (en) * 1994-06-06 2002-02-05 Arnold I. Caplan Biomatrix for tissue regeneration
US5707996A (en) * 1995-11-06 1998-01-13 Macleod Pharmaceuticals, Inc. Pharmaceutical solution and methods for preparation thereof
ES2329953T3 (es) * 1996-04-19 2009-12-02 Osiris Therapeutics, Inc. Regeneracion e incremento de hueso utilizando celulas madre mesenquimales.
US5827740A (en) * 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
CA2296704C (en) * 1997-07-14 2010-10-19 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
AU755888B2 (en) 1998-03-18 2003-01-02 Mesoblast International Sarl Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
AU4094099A (en) * 1998-05-22 1999-12-13 Osiris Therapeutics, Inc. Production of megakaryocytes by co-culturing human mesenchymal stem cells with cd34+ cells
FR2787463B1 (fr) * 1998-12-21 2001-03-30 Neurotech Preparation de cellules de mammifere eventuellement transfectees avec un gene codant pour une substance active et les compositions les contenant
JP2002325572A (ja) * 2000-12-25 2002-11-12 Univ Osaka 外来物質の導入方法
US20030054331A1 (en) 2001-09-14 2003-03-20 Stemsource, Inc. Preservation of non embryonic cells from non hematopoietic tissues
US7585670B2 (en) 2001-12-07 2009-09-08 Cytori Therapeutics, Inc. Automated methods for isolating and using clinically safe adipose derived regenerative cells
US20050095228A1 (en) 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
US7514075B2 (en) 2001-12-07 2009-04-07 Cytori Therapeutics, Inc. Systems and methods for separating and concentrating adipose derived stem cells from tissue
US8404229B2 (en) 2001-12-07 2013-03-26 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to treat acute tubular necrosis
JP4653952B2 (ja) 2001-12-07 2011-03-16 サイトリ セラピューティクス インコーポレイテッド 処理済み脂肪吸引細胞で患者を治療するためのシステムと方法
US20050048035A1 (en) 2001-12-07 2005-03-03 Fraser John K. Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
US20050048036A1 (en) 2001-12-07 2005-03-03 Hedrick Marc H. Methods of using regenerative cells in the treatment of inherited and acquired disorders of the bone, bone marrow, liver, and other tissues
US9597395B2 (en) 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US20050008626A1 (en) 2001-12-07 2005-01-13 Fraser John K. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
ITTO20020311A1 (it) * 2002-04-10 2003-10-10 Medestea Int Spa Procedimento per la preparazione di cellule staminali da tessuto muscolare e tessuto adiposo umano e cellule staminali ottenibili mediante t
ZA200404101B (en) 2003-05-26 2005-03-07 Reliance Life Sciences Pvt Ltd In vitro culture of Mesenchymal Stem Cells (MSC) and a process for the preparation thereof for therapeutic use.
KR101127305B1 (ko) 2003-06-25 2012-04-23 사이토리 테라퓨틱스, 인크. 조직으로부터 재생성 세포를 분리하고 농축시키기 위한시스템 및 방법
EP2298864B1 (en) * 2004-03-22 2017-10-11 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
JP3828905B2 (ja) * 2004-08-05 2006-10-04 株式会社Ｒ＆Ｄセルサイエンス・オプショナルメディコ 局所麻酔薬を含有する細胞凝集抑制剤
US8512724B2 (en) * 2005-06-10 2013-08-20 The Board Of Regents Of The University Of Texas System Antiseptic compositions
WO2007035843A2 (en) 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
US7888119B2 (en) * 2005-10-14 2011-02-15 University Of Central Florida Research Foundation, Inc. Tissue substitutes comprising stem cells and reduced ceria
US20070253931A1 (en) * 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
US8592209B2 (en) * 2006-01-30 2013-11-26 University Of Virginia Patent Foundation Methods of preparing and characterizing mesenchymal stem cell aggregates and uses thereof
US8679809B2 (en) 2006-05-19 2014-03-25 The University Of Hong Kong Cell-matrix microspheres, methods for preparation and applications
EP2617428A1 (en) 2006-08-15 2013-07-24 Agency for Science, Technology and Research Mesenchymal stem cell conditioned medium
US7871605B2 (en) * 2006-11-03 2011-01-18 Aastrom Bioscience, Inc. Mixed cell populations for tissue repair and separation technique for cell processing
JP2008139106A (ja) * 2006-11-30 2008-06-19 Sysmex Corp 骨髄穿刺液収容具及び骨髄穿刺液濾過方法
WO2008073331A2 (en) 2006-12-07 2008-06-19 Teva Pharmaceutical Industries Ltd. Method of generation and expansion of tissue-progenitor cells and mature tissue cells from intact bone marrow or intact umbilical cord tissue
CN101210232B (zh) * 2006-12-28 2012-07-18 天津昂赛细胞基因工程有限公司 一种间充质干细胞保存液
US20110262402A1 (en) 2007-09-07 2011-10-27 Masahiko Kuroda Therapeutic and prophylactic agents for arthritis
EP2210608B1 (en) 2007-11-02 2016-08-31 JCR Pharmaceuticals CO., LTD. Pharmaceutical composition containing human mesenchymal stem cell
WO2010019886A1 (en) 2008-08-14 2010-02-18 Osiris Therapeutics, Inc. Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions
US8048976B2 (en) 2008-09-04 2011-11-01 Amyris, Inc. Polyfarnesenes
US10476476B2 (en) 2016-12-15 2019-11-12 Murata Manufacturing Co., Ltd. MEMS resonator with suppressed spurious modes

Also Published As

Publication number Publication date
US20200197444A1 (en) 2020-06-25
JP2012500214A (ja) 2012-01-05
NZ591146A (en) 2012-10-26
NZ602248A (en) 2014-03-28
JP2018109052A (ja) 2018-07-12
BRPI0917993B1 (pt) 2020-12-29
ES2608974T3 (es) 2017-04-17
BRPI0917993A2 (pt) 2017-10-10
US20230089901A1 (en) 2023-03-23
US20180008642A1 (en) 2018-01-11
EP4477742A3 (en) 2025-02-26
DK2318519T3 (en) 2017-01-16
AU2009281809A1 (en) 2010-02-18
CA2733985C (en) 2016-07-12
EP3124601A1 (en) 2017-02-01
JP7580202B2 (ja) 2024-11-11
AR073069A1 (es) 2010-10-13
MX2011001730A (es) 2011-03-24
AR123811A2 (es) 2023-01-18
WO2010019886A1 (en) 2010-02-18
EP4477742A2 (en) 2024-12-18
US20100068191A1 (en) 2010-03-18
JP2023052211A (ja) 2023-04-11
US20140105872A1 (en) 2014-04-17
JP2020120671A (ja) 2020-08-13
JP2015071610A (ja) 2015-04-16
EP2318519A1 (en) 2011-05-11
EP2318519A4 (en) 2013-07-24
US20250312379A1 (en) 2025-10-09
CA2733985A1 (en) 2010-02-18
AU2009281809B2 (en) 2015-09-17
BRPI0917993B8 (pt) 2021-05-25
EP2318519B1 (en) 2016-10-05
JP2025122125A (ja) 2025-08-20
ZA201101858B (en) 2011-11-30
US8637004B2 (en) 2014-01-28
JP2017081972A (ja) 2017-05-18
JP6025329B2 (ja) 2016-11-16
IL211214A0 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
MX362512B (es) Composiciones purificadas de celulas madre mesenquimales y metodos para purificar composiciones de celulas madre mesenquimales.
UA110054C2 (uk) Розгалужені похідні 3-фенілпропіонової кислоти і їх застосування
CY1120908T1 (el) Μεθοδοι και συστηματα για τον καθαρισμο της μη συμπλεγμενης νευροτοξινης της αλλαντιασης
MX378354B (es) Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.
BR112012028291A2 (pt) composições farmacêuticas e métodos para sua produção
BR112015000106A2 (pt) moduladores heterocíclicos de síntes de lipídio
MX351028B (es) Determinadadas entidades, composiciones y metodos quimicos.
UA115652C2 (uk) Сполука, що містить модифікований олігонуклеотид, комплементарна mir-21
CL2012002627A1 (es) Metodos para aumentar la tolerancia al estres abiotico y/o reducir las consecuencias del estres abiotico en plantas que comprende ponerla en contacto con una composicion que contiene acido dicarboxilico o un derivado.
BRPI0909040B8 (pt) derivados de azetidina e ciclobutano, seus usos, e composição
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
MX342388B (es) Variantes y composiciones que comprenden variantes con alta estabilidad en presencia de un agente quelante.
EP2675892A4 (en) METHOD AND COMPOSITIONS FOR PREPARING PATIENT-SPECIFIC MULTIPOTENTS OF NEURONAL STEM CELLS
AR088920A1 (es) Purificacion de anticuerpos anti-c-met
EA201690520A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
UY32704A (es) Compuestos de 2,3-dihidro-1h-indeno
MX2013007235A (es) Composicion para el cuidado oral acuosa que comprende goma xantana, goma de celulosa y carbomero.
ECSP11010992A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
PY09010618A (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UA111142C2 (uk) Одержання заміщених похідних 2-фторакрилової кислоти
EA201490653A1 (ru) Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств
MX340147B (es) Composiciones farmacéuticas y nutracéuticas del ácido abscísico.
CO6331434A2 (es) Nuevos compuestos
CY1120525T1 (el) Κρυσταλλικη (1r,4r)-6'-φθορο-ν,ν-διμεθυλ-4-φαινυλ-4',9'-διυδρο-3'h-σπειρο[κυκλοεξανο-1,1'-πυρανο[3,4,b]ινδολ]-4-αμινη